Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.

Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, Knelson EH, Xie Y, Lim K, Cejas P, Portell A, Lizotte PH, Ficarro SB, Li S, Chen T, Haikala HM, Wang H, Bahcall M, Gao Y, Shalhout S, Boettcher S, Shin BH, Thai T, Wilkens MK, Tillgren ML, Mushajiang M, Xu M, Choi J, Bertram AA, Ebert BL, Beroukhim R, Bandopadhayay P, Awad MM, Gokhale PC, Kirschmeier PT, Marto JA, Camargo FD, Haq R, Paweletz CP, Wong KK, Barbie DA, Long HW, Gray NS, Jänne PA.

Cancer Cell. 2020 Jan 13;37(1):104-122.e12. doi: 10.1016/j.ccell.2019.12.006.

PMID:
31935369
2.

Principles and methods of integrative chromatin analysis in primary tissues and tumors.

Cejas P, Long HW.

Biochim Biophys Acta Rev Cancer. 2020 Jan;1873(1):188333. doi: 10.1016/j.bbcan.2019.188333. Epub 2019 Nov 22. Review.

PMID:
31759992
3.

Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers.

Ponnusamy S, Asemota S, Schwartzberg LS, Guestini F, McNamara KM, Pierobon M, Font-Tello A, Qiu X, Xie Y, Rao PK, Thiyagarajan T, Grimes B, Johnson DL, Fleming MD, Pritchard FE, Berry MP, Oswaks R, Fine RE, Brown M, Sasano H, Petricoin EF, Long HW, Narayanan R.

iScience. 2019 Nov 22;21:341-358. doi: 10.1016/j.isci.2019.10.038. Epub 2019 Oct 23.

4.

Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ.

Ding L, Su Y, Fassl A, Hinohara K, Qiu X, Harper NW, Huh SJ, Bloushtain-Qimron N, Jovanović B, Ekram M, Zi X, Hines WC, Alečković M, Gil Del Alcazar C, Caulfield RJ, Bonal DM, Nguyen QD, Merino VF, Choudhury S, Ethington G, Panos L, Grant M, Herlihy W, Au A, Rosson GD, Argani P, Richardson AL, Dillon D, Allred DC, Babski K, Kim EMH, McDonnell CH 3rd, Wagner J, Rowberry R, Bobolis K, Kleer CG, Hwang ES, Blum JL, Cristea S, Sicinski P, Fan R, Long HW, Sukumar S, Park SY, Garber JE, Bissell M, Yao J, Polyak K.

Nat Commun. 2019 Sep 13;10(1):4182. doi: 10.1038/s41467-019-12125-5.

5.

Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors.

Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK, Valk GD, Vriens MR, Castillo CF, Ferrone CR, Adar T, Bowden M, Whitton HJ, Da Silva A, Font-Tello A, Long HW, Gaskell E, Shoresh N, Heaphy CM, Sicinska E, Kulke MH, Chung DC, Bernstein BE, Shivdasani RA.

Nat Med. 2019 Oct;25(10):1627. doi: 10.1038/s41591-019-0573-5.

PMID:
31501535
6.

Super-Enhancer-Associated LncRNA UCA1 Interacts Directly with AMOT to Activate YAP Target Genes in Epithelial Ovarian Cancer.

Lin X, Spindler TJ, de Souza Fonseca MA, Corona RI, Seo JH, Dezem FS, Li L, Lee JM, Long HW, Sellers TA, Karlan BY, Noushmehr H, Freedman ML, Gayther SA, Lawrenson K.

iScience. 2019 Jul 26;17:242-255. doi: 10.1016/j.isci.2019.06.025. Epub 2019 Jun 20.

7.

Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors.

Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK, Valk GD, Vriens MR, Castillo CF, Ferrone CR, Adar T, Bowden M, Whitton HJ, Da Silva A, Font-Tello A, Long HW, Gaskell E, Shoresh N, Heaphy CM, Sicinska E, Kulke MH, Chung DC, Bernstein BE, Shivdasani RA.

Nat Med. 2019 Aug;25(8):1260-1265. doi: 10.1038/s41591-019-0493-4. Epub 2019 Jul 1. Erratum in: Nat Med. 2019 Oct;25(10):1627.

8.

A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).

Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, Coggins SA, Nandakumar S, Gerke TA, Pomerantz MM, Qiu X, Zhao H, Atiq M, Khan N, Komura K, Lee GM, Fine SW, Bell C, O'Connor E, Long HW, Freedman ML, Kim B, Kantoff PW.

Clin Cancer Res. 2019 Jul 15;25(14):4480-4492. doi: 10.1158/1078-0432.CCR-18-4046. Epub 2019 Apr 17.

PMID:
30996073
9.

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M.

Cancer Cell. 2019 Mar 18;35(3):401-413.e6. doi: 10.1016/j.ccell.2019.01.008. Epub 2019 Feb 14.

PMID:
30773341
10.

[Clinical analysis of 16 children with traumatic basal ganglia stroke].

Wang GM, Li YB, Wei Q, Han YW, Long HW, Liu XJ.

Zhonghua Er Ke Za Zhi. 2019 Jan 2;57(1):46-49. doi: 10.3760/cma.j.issn.0578-1310.2019.01.011. Chinese.

PMID:
30630231
11.

Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 Overexpression.

Mowery CT, Reyes JM, Cabal-Hierro L, Higby KJ, Karlin KL, Wang JH, Kimmerling RJ, Cejas P, Lim K, Li H, Furusawa T, Long HW, Pellman D, Chapuy B, Bustin M, Manalis SR, Westbrook TF, Lin CY, Lane AA.

Cell Rep. 2018 Nov 13;25(7):1898-1911.e5. doi: 10.1016/j.celrep.2018.10.061.

12.

A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer.

Takeda DY, Spisák S, Seo JH, Bell C, O'Connor E, Korthauer K, Ribli D, Csabai I, Solymosi N, Szállási Z, Stillman DR, Cejas P, Qiu X, Long HW, Tisza V, Nuzzo PV, Rohanizadegan M, Pomerantz MM, Hahn WC, Freedman ML.

Cell. 2018 Jul 12;174(2):422-432.e13. doi: 10.1016/j.cell.2018.05.037. Epub 2018 Jun 14.

13.

VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis.

Cornwell M, Vangala M, Taing L, Herbert Z, Köster J, Li B, Sun H, Li T, Zhang J, Qiu X, Pun M, Jeselsohn R, Brown M, Liu XS, Long HW.

BMC Bioinformatics. 2018 Apr 12;19(1):135. doi: 10.1186/s12859-018-2139-9.

14.

Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling.

Singhal H, Greene ME, Zarnke AL, Laine M, Al Abosy R, Chang YF, Dembo AG, Schoenfelt K, Vadhi R, Qiu X, Rao P, Santhamma B, Nair HB, Nickisch KJ, Long HW, Becker L, Brown M, Greene GL.

Oncotarget. 2017 Sep 28;9(4):4282-4300. doi: 10.18632/oncotarget.21378. eCollection 2018 Jan 12.

15.

A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.

Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay RE, Luoma AM, Tsoucas D, Qiu X, Lim K, Rao P, Long HW, Yuan GC, Doench J, Brown M, Liu XS, Wucherpfennig KW.

Science. 2018 Feb 16;359(6377):770-775. doi: 10.1126/science.aao1710. Epub 2018 Jan 4.

16.

Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer.

Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, Rockowitz S, Drier Y, Bernstein BE, Long HW, Freedman ML, Arora VK, Zheng D, Sawyers CL.

Elife. 2017 Sep 11;6. pii: e27861. doi: 10.7554/eLife.27861.

17.

Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.

Jeselsohn R, Cornwell M, Pun M, Buchwalter G, Nguyen M, Bango C, Huang Y, Kuang Y, Paweletz C, Fu X, Nardone A, De Angelis C, Detre S, Dodson A, Mohammed H, Carroll JS, Bowden M, Rao P, Long HW, Li F, Dowsett M, Schiff R, Brown M.

Proc Natl Acad Sci U S A. 2017 May 30;114(22):E4482-E4491. doi: 10.1073/pnas.1620993114. Epub 2017 May 15.

18.

Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer.

Dreijerink KMA, Groner AC, Vos ESM, Font-Tello A, Gu L, Chi D, Reyes J, Cook J, Lim E, Lin CY, de Laat W, Rao PK, Long HW, Brown M.

Cell Rep. 2017 Mar 7;18(10):2359-2372. doi: 10.1016/j.celrep.2017.02.025.

19.

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.

Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbé DP, Gomez EC, Wang J, Long HW, Xu B, Brown M, Loda M, Sawyers CL, Ellis L, Goodrich DW.

Science. 2017 Jan 6;355(6320):78-83. doi: 10.1126/science.aah4199.

20.

ChiLin: a comprehensive ChIP-seq and DNase-seq quality control and analysis pipeline.

Qin Q, Mei S, Wu Q, Sun H, Li L, Taing L, Chen S, Li F, Liu T, Zang C, Xu H, Chen Y, Meyer CA, Zhang Y, Brown M, Long HW, Liu XS.

BMC Bioinformatics. 2016 Oct 3;17(1):404.

21.

Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles.

Cejas P, Li L, O'Neill NK, Duarte M, Rao P, Bowden M, Zhou CW, Mendiola M, Burgos E, Feliu J, Moreno-Rubio J, Guadalajara H, Moreno V, García-Olmo D, Bellmunt J, Mullane S, Hirsch M, Sweeney CJ, Richardson A, Liu XS, Brown M, Shivdasani RA, Long HW.

Nat Med. 2016 Jun;22(6):685-91. doi: 10.1038/nm.4085. Epub 2016 Apr 25.

PMID:
27111282
22.

Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation.

Gusev A, Shi H, Kichaev G, Pomerantz M, Li F, Long HW, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Zheng W, Pettaway CA, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, John EM, Murphy AB, Signorello LB, Carpten J, Leske MC, Wu SY, Hennis AJ, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Witte JS, Casey G, Kaggwa S, Cook MB, Stram DO, Blot WJ, Eeles RA, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Southey MC, Fitzgerald LM, Gronberg H, Wiklund F, Aly M, Henderson BE, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Teerlink C, Brenner H, Dieffenbach AK, Arndt V, Park JY, Sellers TA, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Spurdle A, Clements JA, Teixeira MR, Pandha H, Michael A, Paulo P, Maia S, Kierzek A; PRACTICAL consortium, Conti DV, Albanes D, Berg C, Berndt SI, Campa D, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Giovannucci E, Hoover R, Hunter DJ, Johansson M, Kraft P, Le Marchand L, Lindström S, Navarro C, Overvad K, Riboli E, Siddiq A, Stevens VL, Trichopoulos D, Vineis P, Yeager M, Trynka G, Raychaudhuri S, Schumacher FR, Price AL, Freedman ML, Haiman CA, Pasaniuc B.

Nat Commun. 2016 Apr 7;7:10979. doi: 10.1038/ncomms10979.

23.

The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis.

Pomerantz MM, Li F, Takeda DY, Lenci R, Chonkar A, Chabot M, Cejas P, Vazquez F, Cook J, Shivdasani RA, Bowden M, Lis R, Hahn WC, Kantoff PW, Brown M, Loda M, Long HW, Freedman ML.

Nat Genet. 2015 Nov;47(11):1346-51. doi: 10.1038/ng.3419. Epub 2015 Oct 12.

24.

Methyl protodioscin induces G2/M cell cycle arrest and apoptosis in A549 human lung cancer cells.

Bai Y, Qu XY, Yin JQ, Wu L, Jiang H, Long HW, Jia Q.

Pharmacogn Mag. 2014 Jul;10(39):318-24. doi: 10.4103/0973-1296.137373.

25.

Wogonin has multiple anti-cancer effects by regulating c-Myc/SKP2/Fbw7α and HDAC1/HDAC2 pathways and inducing apoptosis in human lung adenocarcinoma cell line A549.

Chen XM, Bai Y, Zhong YJ, Xie XL, Long HW, Yang YY, Wu SG, Jia Q, Wang XH.

PLoS One. 2013 Nov 12;8(11):e79201. doi: 10.1371/journal.pone.0079201. eCollection 2013.

26.

HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia.

Galbraith MD, Allen MA, Bensard CL, Wang X, Schwinn MK, Qin B, Long HW, Daniels DL, Hahn WC, Dowell RD, Espinosa JM.

Cell. 2013 Jun 6;153(6):1327-39. doi: 10.1016/j.cell.2013.04.048.

27.

CistromeFinder for ChIP-seq and DNase-seq data reuse.

Sun H, Qin B, Liu T, Wang Q, Liu J, Wang J, Lin X, Yang Y, Taing L, Rao PK, Brown M, Zhang Y, Long HW, Liu XS.

Bioinformatics. 2013 May 15;29(10):1352-4. doi: 10.1093/bioinformatics/btt135. Epub 2013 Mar 18.

28.

A real options approach to clinical faculty salary structure.

Kahn MJ, Long HW.

J Health Care Finance. 2012 Fall;39(1):87-96.

PMID:
23155746
29.

Complementary and alternative medicine: opportunities and challenges.

Martin WM, Long HW.

J Health Care Finance. 2007 Winter;34(2):89-104.

PMID:
18972997
30.

The Master of Medical Management (MMM) degree: an analysis of alumni perceptions.

Martin WF, Long HW, Culbertson RA, Beyt E.

J Health Adm Educ. 2007 Fall;24(4):391-8.

PMID:
18578267
31.

Multiple-pulse nuclear magnetic resonance of optically pumped xenon in a low magnetic field.

Raftery D, Long HW, Shykind D, Grandinetti PJ, Pines A.

Phys Rev A. 1994 Jul;50(1):567-574. No abstract available.

PMID:
9910927
32.

Health policy guided by five questions.

Long HW.

Physician Exec. 1991 Sep-Oct;17(5):9-15.

PMID:
10114722
33.

Fiscal health of hospitals in a decade of Medicare.

Long HW.

Physician Exec. 1991 May-Jun;17(3):51-5.

PMID:
10111674
34.

But 'twas a famous victory.

Long HW.

Physician Exec. 1990 May-Jun;16(3):34-5.

PMID:
10113234
35.

Do these guys know why they're applauding?

Long HW.

Physician Exec. 1990 Mar-Apr;16(2):25-6.

PMID:
10113255
36.

Medicare catastrophic coverage: a postmortem.

Long HW.

Physician Exec. 1990 Jan-Feb;16(1):12-4.

PMID:
10113120
37.

Emergency departments need aggressive management.

Long HW, Lauve RM.

Physician Exec. 1989 Nov-Dec;15(6):40-2.

PMID:
10313408
38.

Toward a definition of quality.

Klint RB, Long HW.

Physician Exec. 1989 Sep-Oct;15(5):7-11.

PMID:
10316428
39.

Toward better care and improved payment.

Long HW, Lauve RM.

Physician Exec. 1989 Jul-Aug;15(4):29-31.

PMID:
10313372
40.

Medicare's ESRD program, Part 2: Transplantation.

Long HW, Lauve RM.

Physician Exec. 1989 May-Jun;15(3):31-3.

PMID:
10313122
41.

Medicare's ESRD Program, Part 1: Dialysis.

Long HW.

Physician Exec. 1989 Mar-Apr;15(2):24-6.

PMID:
10313034
42.

Are your economic incentives self-defeating?

Long HW.

Physician Exec. 1989 Jan-Feb;15(1):41-2.

PMID:
10312891
43.

Group practices may ignore economic realities: commingling of rents and returns.

Long HW.

Physician Exec. 1988 Sep-Oct;14(5):33-5. No abstract available.

PMID:
10312884
44.

Health economics 1988 law makes significant changes in Medicare.

Long HW.

Physician Exec. 1988 Jul-Aug;14(4):26-8. No abstract available. Erratum in: Physician Exec 1988 Sep-Oct;14(5):35.

PMID:
10312702
45.

Home health care: payment and growth.

Long HW.

Physician Exec. 1988 May-Jun;14(3):27-8.

PMID:
10312565
46.

Critics ignore volume in their assessment of health care costs.

Long HW.

Physician Exec. 1988 Mar-Apr;14(2):25-6. No abstract available.

PMID:
10312467
47.

A Medicare primer, Part 2: The provider's view.

Long HW.

Physician Exec. 1988 Jan-Feb;14(1):30-2. No abstract available.

PMID:
10312412
48.

A Medicare primer. Part 1: The beneficiary's view.

Long HW.

Physician Exec. 1987 Nov-Dec;13(6):27-8. No abstract available.

PMID:
10312351
49.

National health insurance: some policy options.

Long HW.

Physician Exec. 1987 Sep-Oct;13(5):26-7. No abstract available.

PMID:
10312296
50.

Medicare catastrophic coverage proposals.

Long HW.

Physician Exec. 1987 Jul-Aug;13(4):31-2. No abstract available.

PMID:
10312211

Supplemental Content

Support Center